Effects of nonprescription therapies on vestibular migraine: a questionnaire‐based observational study
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16314 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Imelda P Hannigan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Central Clinical School, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Migraine Disorders, Vertigo. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Garnett Passe and Rodney Williams Memorial Foundation, National Health and Medical Research Council.
Abstract (Originalsprache)
Background
Vestibular migraine (VM) is a common cause of recurrent vertigo. Migraine headache preventative therapies are currently prescribed to control vertigo symptoms in VM. Clinical trials of nutraceuticals for migraine headache prevention have shown positive outcomes, but, to date, there have been no studies to assess their effectiveness in the management of VM.
Aims
To report the effects of nonprescription therapy management on VM symptoms.
Methods
We undertook a prospective, questionnaire‐based assessment of patients diagnosed with VM between November 2019 and August 2021 at two Sydney tertiary referral clinics. Patients were advised on optimising sleep, hydration, exercise and nutrition and instructed to use an over‐the‐counter combination product containing riboflavin 200 mg, magnesium 150 mg, coenzyme Q10 75 mg and feverfew 200 mcg. Symptom severity and frequency were assessed using the Dizziness Handicap Inventory (DHI), the Vertigo Symptom Score short‐form (VSS‐sf) and two visual analogue scales for severity (VAS‐s) and frequency (VAS‐f) before and 3 months after commencing treatment.
Result
In 82 participants (78% female; mean age, 44 ± 14 years) we recorded a decrease in DHI (mean, 16.8 [95% confidence interval (CI), 12.8–20.9], VSS‐sf (9.3, 7.1–11.5), VAS‐s (3.0, 2.2–3.8) and VAS‐f (2.8, 2.1–3.4), equating to an improvement of 44.1%, 44.9%, 44.1% and 38.9% for each measure respectively. On the DHI and VSS‐sf, 41 (50%) and 44 (53.7%) patients showed improvement in their symptoms; 39 (47.6%) and 36 (43.9%) patients noted no change and two patients reported worsening. The supplement was well‐tolerated.
Conclusions
The results provide preliminary evidence that VM symptom frequency and severity can be reduced by using nonprescription therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Clinical School, University of Sydney, Sydney, New South Wales, Australia.
- Blacktown Neurology Clinic, Blacktown, New South Wales, Australia.
- Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
- Biostatistics and Data Science Division, The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia.
- Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
ORCID-Profile: Imelda P Hannigan
Förderung
- Garnett Passe and Rodney Williams Memorial Foundation
- National Health and Medical Research Council
Zitieren
APA
Hannigan, I. P., Rosengren, S. M., Di Tanna, G. L., Watson, S. R. D., & Welgampola, M. S. (2024). Effects of nonprescription therapies on vestibular migraine: a questionnaire‐based observational study. Internal Medicine Journal. https://doi.org/10.1111/imj.16314
Vancouver
Hannigan IP, Rosengren SM, Di Tanna GL, Watson SRD, Welgampola MS. Effects of nonprescription therapies on vestibular migraine: a questionnaire‐based observational study. Internal Medicine Journal. 2024. doi:10.1111/imj.16314
BibTeX
@article{Hannigan2024,
author = {Hannigan, Imelda P and Rosengren, Sally M and Di Tanna, Gian L and Watson, Shaun R D and Welgampola, Miriam S},
title = {Effects of nonprescription therapies on vestibular migraine: a questionnaire‐based observational study},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16314}
}
EUVIMED